Cowen Prime Services LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 6.6% during the fourth quarter, Holdings Channel reports. The fund owned 103,220 shares of the biopharmaceutical company’s stock after selling 7,260 shares during the quarter. Pfizer makes up approximately 2.7% of Cowen Prime Services LLC’s investment portfolio, making the stock its 10th biggest position. Cowen Prime Services LLC’s holdings in Pfizer were worth $4,506,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Advocacy Wealth Management Services LLC boosted its position in Pfizer by 48.2% during the fourth quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 258 shares during the last quarter. Contravisory Investment Management Inc. boosted its position in Pfizer by 182.6% during the fourth quarter. Contravisory Investment Management Inc. now owns 1,153 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 745 shares during the last quarter. Vestor Capital LLC acquired a new stake in Pfizer during the third quarter worth approximately $53,000. Arlington Partners LLC boosted its position in Pfizer by 64.7% during the fourth quarter. Arlington Partners LLC now owns 2,141 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 841 shares during the last quarter. Finally, Ironwood Financial llc boosted its position in Pfizer by 91.0% during the fourth quarter. Ironwood Financial llc now owns 2,229 shares of the biopharmaceutical company’s stock worth $97,000 after acquiring an additional 1,062 shares during the last quarter. Hedge funds and other institutional investors own 69.53% of the company’s stock.

In other news, insider Mikael Dolsten sold 149,553 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $43.55, for a total value of $6,513,033.15. Following the transaction, the insider now owns 390,097 shares of the company’s stock, valued at approximately $16,988,724.35. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $42.83, for a total transaction of $642,450.00. Following the completion of the transaction, the insider now directly owns 124,994 shares in the company, valued at approximately $5,353,493.02. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 332,526 shares of company stock worth $14,346,539. 0.09% of the stock is currently owned by insiders.

NYSE:PFE opened at $42.09 on Tuesday. The company has a current ratio of 1.57, a quick ratio of 1.33 and a debt-to-equity ratio of 0.52. The company has a market cap of $248.41 billion, a price-to-earnings ratio of 14.03, a P/E/G ratio of 2.55 and a beta of 0.75. Pfizer Inc. has a fifty-two week low of $34.37 and a fifty-two week high of $46.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.01. The company had revenue of $13.98 billion for the quarter, compared to the consensus estimate of $13.92 billion. Pfizer had a net margin of 20.79% and a return on equity of 26.02%. Pfizer’s revenue was up 2.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.62 earnings per share. On average, equities analysts predict that Pfizer Inc. will post 2.86 earnings per share for the current fiscal year.

A number of brokerages recently issued reports on PFE. Credit Suisse Group set a $45.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, January 1st. Cantor Fitzgerald set a $53.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Sunday, December 30th. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, April 3rd. Bank of America raised their target price on shares of Pfizer from $45.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. Finally, Citigroup reaffirmed a “neutral” rating and set a $41.00 price target on shares of Pfizer in a research note on Wednesday, February 20th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and seven have assigned a buy rating to the company’s stock. Pfizer currently has an average rating of “Hold” and a consensus target price of $45.61.

TRADEMARK VIOLATION NOTICE: “Pfizer Inc. (PFE) Position Cut by Cowen Prime Services LLC” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2019/04/16/pfizer-inc-pfe-position-cut-by-cowen-prime-services-llc.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: Closed-End Mutual Funds (CEFs)

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.